Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Alpine Immune Sciences Inc
ALPNCurrent price
7.6 USD
0 USD (0.00%)
Last closed
7.6 USD
Company
www.alpineimmunesciences.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 456 779 776 USD
Yield for 12 month
-34.82 %
1Y
3Y
5Y
10Y
15Y
ALPN
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated. Address: 188 East Blaine Street, Seattle, WA, United States, 98102
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
62 USDP/E ratio
–Dividend Yield
–Current Year
+58 876 000 USD
Last Year
+30 064 000 USD
Current Quarter
+7 032 000 USD
Last Quarter
+30 853 000 USD
Current Year
+58 300 000 USD
Last Year
+29 467 000 USD
Current Quarter
+6 885 000 USD
Last Quarter
+30 705 000 USD
Key Figures ALPN
1 year
3 years
5 years
10 years
EBITDA
-50 771 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-10.1 %
PEG Ratio
–
Return On Equity TTM
-14.67 %
Wall Street Target Price
62 USD
Revenue TTM
56 521 000 USD
Book Value
5.08 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-25.1 %
Dividend Yield
–
Gross Profit TTM
-40 179 000 USD
Earnings per share
-0.64 USD
Diluted Eps TTM
-0.64 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-65.17 %
Dividend Analytics ALPN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALPN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:4
Payout Ratio
–
Last Split Date
25.07.2017
Dividend Date
25.07.2017
Stock Valuation ALPN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
66.2856
Price Sales TTM
71.6783
Enterprise Value EBITDA
-124.2599
Price Book MRQ
12.8686
Financials ALPN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ALPN
For 52 weeks
7.5 USD
64.97 USD
50 Day MA
53.15 USD
Shares Short Prior Month
4 742 079
200 Day MA
26.84 USD
Short Ratio
0.96
Shares Short
3 887 995
Short Percent
8.27 %
BeatStart